Drug
Maraviroc 300 mg
Maraviroc 300 mg is a pharmaceutical drug with 6 clinical trials. Historical success rate of 66.7%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 4 completed trials
Completion Rate
67%(4/6)
Active Trials
0(0%)
Results Posted
75%(3 trials)
Terminated
2(33%)
Phase Distribution
Ph phase_1
1
17%
Ph phase_4
1
17%
Ph phase_2
4
67%
Phase Distribution
1
Early Stage
4
Mid Stage
1
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
4(66.7%)
Phase 4Post-market surveillance
1(16.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
66.7%
4 of 6 finished
Non-Completion Rate
33.3%
2 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(4)
Terminated(2)
Detailed Status
Completed4
Terminated2
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
66.7%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (16.7%)
Phase 24 (66.7%)
Phase 41 (16.7%)
Trials by Status
completed467%
terminated233%
Recent Activity
0 active trials
Showing 5 of 6
completedphase_2
Safety of Maraviroc for Post-stroke Depression
NCT05932550
completedphase_1
Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation
NCT00948753
terminatedphase_2
Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).
NCT04441385
terminatedphase_2
Maraviroc to Augment Rehabilitation Outcomes After Stroke
NCT03172026
completedphase_2
Phase II Maraviroc for GVHD Prevention
NCT01785810
Clinical Trials (6)
Showing 6 of 6 trials
NCT05932550Phase 2
Safety of Maraviroc for Post-stroke Depression
NCT00948753Phase 1
Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation
NCT04441385Phase 2
Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).
NCT03172026Phase 2
Maraviroc to Augment Rehabilitation Outcomes After Stroke
NCT01785810Phase 2
Phase II Maraviroc for GVHD Prevention
NCT03402815Phase 4
Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6